Top in ID: White House’s plan to end emergency declarations; hybrid COVID-19 immunity
Click Here to Manage Email Alerts
The Biden administration plans on ending the public health emergency and national emergency declarations related to COVID-19 on May 11, according to a White House statement.
The announcement falls in line with the Biden administration’s assurance that the United States would receive a 60-day “wind-down” before the end of the declarations. It was the top story in infectious disease last week.
Another top story was about a study on the protective effects of hybrid COVID-19 immunity. Researchers found that patients who were vaccinated and previously infected with SARS-CoV-2 had a 97% lower likelihood of developing severe infection 1 year after the last vaccination or infection.
Read these and more top stories in infectious disease below:
White House plans to end COVID-19 health emergencies in May
The Biden administration plans to end the COVID-19 emergency declarations on May 11, the White House announced. Read more.
Hybrid COVID-19 immunity offers higher protection than previous infection alone
People who are vaccinated and have previously been infected with SARS-CoV-2 had a 97% reduced chance of severe SARS-CoV-2 infection 1 year after their last vaccination or infection, researchers determined. Read more.
‘Unusual’ exposures identified among HCP in M. tuberculosis outbreak
A tuberculosis outbreak, which was linked to a viable bone allograft product contaminated with Mycobacterium tuberculosis, resulted in “unusual” exposures for health care personnel, according to the outbreak investigation. Read more.
7 days of antibiotics effective for preventing recurrent cUTI among hospitalized adults
Another study has demonstrated that a shorter course of antibiotics may be better, this time for the treatment of complicated UTIs when antibiotics with comparable IV and oral bioavailability are administered. Read more.
HPV vaccination safe, effective for mid-adult patients at risk for future infection
Including mid-adults in HPV vaccination efforts is safe and effective, while remaining cost effective, according to a narrative review of existing data. Read more.